<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244097</url>
  </required_header>
  <id_info>
    <org_study_id>MS-273-2019</org_study_id>
    <nct_id>NCT04244097</nct_id>
  </id_info>
  <brief_title>The Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Pain in Laparoscopic Cholecystectomy</brief_title>
  <acronym>RCTcompstud</acronym>
  <official_title>The Evaluation of the Analgesic Effect of Intraperitoneal Bupivacaine Versus Bupivacaine With Neostigmine on Postoperative Pain in Laparoscopic Cholecystectomy:A Prospective, Randomized, Comparative, Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injection of intraperitoneal bupivacaine revealed an analgesic effect whether injected alone
      or in combination with other adjuvants, which increase duration of analgesia and decrease the
      dose of administered bupivacaine thus minimizing its side effects e.g. Opioids,
      Corticosteroids and Magnesium sulphate.

      Neostigmine, a cholinesterase inhibitor that produces muscarinic receptor-mediated analgesia,
      increased postoperative analgesia when combined with local anaesthetics. Peripheral afferent
      nerve fibres contain muscarinic receptors, these could be a good target for pain suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of neostigmine as adjuvant to intraperitoneal bupivacaine was not previously
      investigated. In this study the investigators will compare the analgesic effect of
      bupivacaine alone and bupivacaine in combination with neostigmine when injected
      intraperitoneal in patients undergoing laparoscopic cholecystectomy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.
Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Patients will be randomly allocated to one of two groups with the help of computer generated random number tables in opaque sealed envelopes prepared by an anaesthesiologist not part of the study. The envelops will be opened by the staff nurse, and peritoneal solution will be prepared according to group allocation by anaesthesiologist who is not involved in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time of first analgesic requirements (in hours) after extubation</measure>
    <time_frame>24 Hours post-operatively.</time_frame>
    <description>hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Total dose of intravenous pethidine (mg/24 hours).</measure>
    <time_frame>24 hours</time_frame>
    <description>milligram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The use of intra-operative rescue analgesia.</measure>
    <time_frame>intraoperative period</time_frame>
    <description>milligram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The severity of post-operative shoulder pain assessed by visual analogue scale</measure>
    <time_frame>24 Hours post-operatively.</time_frame>
    <description>segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain 0 (no pain), 10(worst pain). The common format is a horizontal bar or line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• The severity of post-operative abdominal pain assessed by visual analogue scale</measure>
    <time_frame>24 hours posoperatively</time_frame>
    <description>segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain 0 (no pain), 10(worst pain). The common format is a horizontal bar or line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Post-operative nausea and vomiting assessed by postoperative nausea and vomiting score</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>A simplified risk score for predicting postoperative nausea and vomiting female gender, history of PONV and/or motion sickness, non-smoking status, and postoperative use of opioids. When 0, 1, 2, 3, or 4 factors are present, the risk of postoperative nausea and vomiting is 10%, 20%, 40%, 60%, or 80%, respectively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BN group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.</description>
    <arm_group_label>B group</arm_group_label>
    <arm_group_label>BN group</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>after induction of general anesthesia and before the start of surgery, after inflating the pneumoperitoneum and before any surgical manipulation, the surgeon infuse 50 mL of blinded solution (bupivacaine or bupivacaine neostigmine) intraperitoneally to the sub-diaphragmatic space and gall bladder area guided by the camera and the patients are kept in Trendelenburg position for 5-10 minutes. Thereafter all patients will be positioned in the anti-Trendelenburg position to start the surgery and the laparoscopic procedure will be carried out in a standard fashion.</description>
    <arm_group_label>BN group</arm_group_label>
    <other_name>prostigmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • American Society of Anaesthesiologist (ASA) I-II.

               -  Age 18 - 60 years.

               -  Elective laparoscopic cholecystectomy.

               -  Body Mass Index (BMI) &lt;35 (kg/m2).

        Exclusion Criteria:

          -  • Anaphylaxis to local anaesthetics.

               -  Anaphylaxis to Neostigmine.

               -  American Society of Anaesthesiologist (ASA) III-IV.

               -  Chronic pain diseases.

               -  Acute cholecystitis.

               -  Psychological or nervous system diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Fa Habib, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr El Aini -Faculty Of Medicine- Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sara Farouk Kassem Habib</name>
      <address>
        <city>Cairo</city>
        <state>El Azbakeya</state>
        <zip>2222</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Khurana S, Garg K, Grewal A, Kaul TK, Bose A. A comparative study on postoperative pain relief in laparoscopic cholecystectomy: Intraperitoneal bupivacaine versus combination of bupivacaine and buprenorphine. Anesth Essays Res. 2016 Jan-Apr;10(1):23-8. doi: 10.4103/0259-1162.164731.</citation>
    <PMID>26957685</PMID>
  </results_reference>
  <results_reference>
    <citation>LAURETTI G. Postoperative analgesia by intra-articular and epidural neostigmine following knee surgery. Reg Anesth Pain Med [Internet]. 1999 Jun;24(3):17.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Sara Farouk Kassem Habib</investigator_full_name>
    <investigator_title>lecturer of anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>results of the study or medical data like vital signs only could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>2 months after publication</ipd_time_frame>
    <ipd_access_criteria>data concerning results charts will be available by contacting principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

